Operaciones Sarepta Therapeutics, Inc. - SRPT CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.85 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Sarepta Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Cierre previo* | 124.72 |
Abrir* | 125 |
Cambio de 1 año* | 67.58% |
Rango del día* | 123.03 - 125 |
Rango de 52 semanas | 61.28-159.89 |
Volumen medio (10 días) | 1.79M |
Volumen medio (3 meses) | 38.47M |
Capitalización de mercado | 11.63B |
Ratio P/E | -100.00K |
Acciones en circulación | 93.15M |
Ingresos | 975.68M |
EPS | -12.69 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.00 |
Próxima fecha de resultados | Jul 31, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
May 30, 2023 | 124.72 | -2.16 | -1.70% | 126.88 | 127.55 | 123.89 |
May 26, 2023 | 126.70 | -1.43 | -1.12% | 128.13 | 128.70 | 125.73 |
May 25, 2023 | 128.29 | -0.56 | -0.43% | 128.85 | 130.79 | 125.20 |
May 24, 2023 | 130.77 | -3.49 | -2.60% | 134.26 | 138.75 | 128.06 |
May 23, 2023 | 146.34 | -0.46 | -0.31% | 146.80 | 149.96 | 146.15 |
May 22, 2023 | 148.60 | 0.51 | 0.34% | 148.09 | 151.64 | 148.05 |
May 19, 2023 | 148.45 | 1.54 | 1.05% | 146.91 | 149.24 | 145.47 |
May 18, 2023 | 146.04 | -1.49 | -1.01% | 147.53 | 148.58 | 144.09 |
May 17, 2023 | 148.30 | -0.15 | -0.10% | 148.45 | 149.82 | 144.53 |
May 16, 2023 | 148.31 | -4.88 | -3.19% | 153.19 | 153.43 | 147.50 |
May 15, 2023 | 155.77 | 6.59 | 4.42% | 149.18 | 159.63 | 146.35 |
May 11, 2023 | 119.53 | -0.42 | -0.35% | 119.95 | 120.23 | 113.09 |
May 10, 2023 | 120.52 | -11.25 | -8.54% | 131.77 | 134.60 | 120.52 |
May 9, 2023 | 124.84 | -0.03 | -0.02% | 124.87 | 128.53 | 124.09 |
May 8, 2023 | 126.68 | -4.16 | -3.18% | 130.84 | 130.84 | 125.74 |
May 5, 2023 | 130.88 | 1.45 | 1.12% | 129.43 | 132.26 | 128.46 |
May 4, 2023 | 129.54 | 4.30 | 3.43% | 125.24 | 130.86 | 124.64 |
May 3, 2023 | 125.14 | 5.68 | 4.75% | 119.46 | 126.45 | 119.46 |
May 2, 2023 | 123.57 | -0.05 | -0.04% | 123.62 | 126.82 | 123.23 |
May 1, 2023 | 124.85 | 2.84 | 2.33% | 122.01 | 126.18 | 121.37 |
Sarepta Therapeutics, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
Friday, June 2, 2023 | ||
Hora (UTC) (UTC) 13:00 | País US
| Evento Sarepta Therapeutics Inc Annual Shareholders Meeting Sarepta Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Thursday, June 8, 2023 | ||
Hora (UTC) (UTC) 14:00 | País US
| Evento Sarepta Therapeutics Inc Annual Shareholders Meeting Sarepta Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Monday, July 31, 2023 | ||
Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 Sarepta Therapeutics Inc Earnings Release Q2 2023 Sarepta Therapeutics Inc Earnings ReleaseForecast -Previous - |
Tuesday, October 31, 2023 | ||
Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Sarepta Therapeutics Inc Earnings Release Q3 2023 Sarepta Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 933.013 | 701.887 | 540.099 | 380.833 | 301.034 |
Ingresos | 933.013 | 701.887 | 540.099 | 380.833 | 301.034 |
Coste de los ingresos, total | 139.989 | 97.049 | 63.382 | 56.586 | 34.193 |
Beneficio bruto | 793.024 | 604.838 | 476.717 | 324.247 | 266.841 |
Gastos totales de explotación | 1597.23 | 1064.08 | 996.193 | 1086.4 | 644.662 |
Gastos de venta/general/administración Gastos, total | 451.421 | 282.66 | 317.875 | 284.812 | 207.761 |
Investigación y desarrollo | 877.09 | 771.182 | 722.343 | 560.909 | 401.843 |
Ingresos de explotación | -664.217 | -362.198 | -456.094 | -705.563 | -343.628 |
Ingresos por intereses (gastos), netos No operativos | -30.06 | -55.971 | -101.977 | -18.982 | |
Ingresos netos antes de impuestos | -689.963 | -418.948 | -553.065 | -713.88 | -362.61 |
Ingresos netos después de impuestos | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Beneficio neto antes de partidas extra. Elementos | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Ingresos netos | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Beneficio neto diluido | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Promedio ponderado de acciones diluidas | 87.559 | 81.262 | 77.956 | 73.615 | 66.25 |
BPA diluido sin partidas extraordinarias | -8.03445 | -5.15345 | -7.10821 | -9.71371 | -5.46291 |
BPA normalizado diluido | -7.08411 | -5.85345 | -8.0093 | -7.27209 | -5.46291 |
Depreciation / Amortization | 0.714 | 0.706 | 0.662 | 0.849 | 0.865 |
Gastos (ingresos) extraordinarios | 128.016 | -87.512 | -108.069 | 183.24 | 0 |
Otros, netos | 4.314 | -0.779 | 5.006 | -8.317 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Ingresos totales | 253.5 | 258.427 | 230.269 | 233.487 | 210.83 |
Ingresos | 253.5 | 258.427 | 230.269 | 233.487 | 210.83 |
Coste de los ingresos, total | 35.017 | 30.799 | 39.952 | 37.795 | 31.443 |
Beneficio bruto | 218.483 | 227.628 | 190.317 | 195.692 | 179.387 |
Gastos totales de explotación | 778.917 | 367.835 | 487.065 | 444.619 | 297.711 |
Gastos de venta/general/administración Gastos, total | 110.714 | 120.478 | 104.787 | 154.316 | 71.84 |
Investigación y desarrollo | 245.679 | 213.804 | 216.707 | 252.329 | 194.25 |
Depreciation / Amortization | 0.178 | 0.179 | 0.178 | 0.179 | 0.178 |
Gastos (ingresos) extraordinarios | 387.329 | 2.575 | 125.441 | 0 | 0 |
Ingresos de explotación | -525.417 | -109.408 | -256.796 | -211.132 | -86.881 |
Ingresos por intereses (gastos), netos No operativos | 2.953 | 2.438 | -3.256 | -13.619 | -15.623 |
Otros, netos | 9.754 | 5.664 | 3.634 | -3.342 | -1.642 |
Ingresos netos antes de impuestos | -512.71 | -101.306 | -256.418 | -228.093 | -104.146 |
Ingresos netos después de impuestos | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Beneficio neto antes de partidas extra. Elementos | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Ingresos netos | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Beneficio neto diluido | -516.755 | -109.244 | -257.738 | -231.481 | -105.025 |
Promedio ponderado de acciones diluidas | 88.186 | 87.841 | 87.628 | 87.511 | 87.253 |
BPA diluido sin partidas extraordinarias | -5.85983 | -1.24366 | -2.94127 | -2.64516 | -1.20368 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -3.00491 | -1.2246 | -2.01079 | -2.64516 | -1.20368 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Activo Corriente | 2557.86 | 2604.1 | 2485.2 | 1468.91 | 1426.18 |
Efectivo e inversiones a corto plazo | 1989.37 | 2115.87 | 1938.57 | 1124.75 | 1173.91 |
Efectivo y Equivalentes | 966.777 | 2115.87 | 1502.65 | 835.08 | 370.829 |
Inversiones a corto plazo | 1022.6 | 0 | 435.923 | 289.668 | 803.083 |
Total deudores, neto | 259.697 | 171.637 | 138.583 | 93.938 | 64.436 |
Accounts Receivable - Trade, Net | 214.628 | 152.99 | 101.34 | 90.879 | 49.044 |
Total Inventory | 203.968 | 186.212 | 231.961 | 171.379 | 125.445 |
Prepaid Expenses | 30.645 | 30.583 | 37.586 | 19.323 | 22.006 |
Other Current Assets, Total | 74.177 | 99.798 | 138.495 | 59.525 | 40.384 |
Total Assets | 3128.37 | 3147.97 | 2984.72 | 1822.82 | 1642.07 |
Property/Plant/Equipment, Total - Net | 244.991 | 236.687 | 282.191 | 167.553 | 97.024 |
Property/Plant/Equipment, Total - Gross | 393.867 | 349.319 | 358.218 | 218.548 | 125.173 |
Accumulated Depreciation, Total | -148.876 | -112.632 | -76.027 | -50.995 | -28.149 |
Intangibles, Net | 7.578 | 14.239 | 13.628 | 12.497 | 11.574 |
Other Long Term Assets, Total | 286.615 | 258.057 | 164.904 | 141.922 | 75.555 |
Total Current Liabilities | 619.604 | 452.733 | 416.026 | 264.767 | 173.69 |
Accounts Payable | 95.875 | 76.741 | 111.09 | 68.094 | 33.829 |
Accrued Expenses | 353.18 | 224.601 | 171.865 | 148.124 | 107.648 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | ||||
Other Current Liabilities, Total | 170.549 | 151.391 | 133.071 | 48.549 | 32.213 |
Total Liabilities | 2743.42 | 2219.97 | 2222.96 | 1004.64 | 609.799 |
Total Long Term Debt | 1544.29 | 1096.88 | 992.493 | 681.9 | 420.554 |
Long Term Debt | 1544.29 | 1096.88 | 992.493 | 681.9 | 420.554 |
Other Liabilities, Total | 579.52 | 670.356 | 814.44 | 57.968 | 15.555 |
Total Equity | 384.95 | 928.009 | 761.759 | 818.187 | 1032.28 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.009 | 0.009 | 0.008 | 0.008 | 0.007 |
Additional Paid-In Capital | 4296.84 | 4134.77 | 3609.88 | 3112.13 | 2611.29 |
Retained Earnings (Accumulated Deficit) | -3910.24 | -3206.75 | -2848.13 | -2294 | -1578.93 |
Other Equity, Total | -1.664 | -0.02 | 0.003 | 0.05 | -0.099 |
Total Liabilities & Shareholders’ Equity | 3128.37 | 3147.97 | 2984.72 | 1822.82 | 1642.07 |
Total Common Shares Outstanding | 87.9501 | 87.127 | 79.3743 | 75.1849 | 71.0719 |
Long Term Investments | 31.321 | 34.892 | 38.799 | 31.937 | 31.739 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 2488.38 | 2557.86 | 2625.93 | 2469.3 | 2530.95 |
Efectivo e inversiones a corto plazo | 1882.1 | 1989.37 | 2072.48 | 1928.02 | 2013.43 |
Efectivo y Equivalentes | 871.668 | 966.777 | 1038.62 | 868.565 | 1233.88 |
Inversiones a corto plazo | 1010.43 | 1022.6 | 1033.86 | 1059.45 | 779.548 |
Total deudores, neto | 288.076 | 259.697 | 223.45 | 230.275 | 197.201 |
Accounts Receivable - Trade, Net | 223.836 | 214.628 | 201.509 | 203.854 | 178.194 |
Total Inventory | 202.675 | 203.968 | 221.192 | 208.095 | 198.997 |
Prepaid Expenses | 28.73 | 30.645 | 25.392 | 23.604 | 25.766 |
Other Current Assets, Total | 86.799 | 74.177 | 83.411 | 79.307 | 95.558 |
Total Assets | 3059.79 | 3128.37 | 3156.15 | 2996.85 | 3056.15 |
Property/Plant/Equipment, Total - Net | 244.878 | 244.991 | 224.039 | 230.291 | 233.23 |
Intangibles, Net | 7.199 | 7.578 | 13.057 | 13.062 | 13.328 |
Long Term Investments | 31 | 31.321 | 33.244 | 33.234 | 33.394 |
Other Long Term Assets, Total | 288.332 | 286.615 | 259.88 | 250.966 | 245.255 |
Total Current Liabilities | 536.884 | 619.604 | 602.916 | 545.566 | 454.962 |
Accounts Payable | 106.71 | 95.875 | 118.461 | 56.207 | 54.007 |
Accrued Expenses | 260.77 | 353.18 | 301.056 | 315.338 | 224.935 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 169.404 | 170.549 | 183.399 | 174.021 | 176.02 |
Total Liabilities | 2347.04 | 2743.42 | 2725.31 | 2270.4 | 2199.27 |
Total Long Term Debt | 1234.28 | 1544.29 | 1542.77 | 1100.87 | 1098.85 |
Long Term Debt | 1234.28 | 1544.29 | 1542.77 | 1100.87 | 1098.85 |
Other Liabilities, Total | 575.869 | 579.52 | 579.623 | 623.957 | 645.459 |
Total Equity | 712.749 | 384.95 | 430.84 | 726.457 | 856.886 |
Common Stock | 0.009 | 0.009 | 0.009 | 0.009 | 0.009 |
Additional Paid-In Capital | 5140.15 | 4296.84 | 4235.03 | 4272.19 | 4168.96 |
Retained Earnings (Accumulated Deficit) | -4426.99 | -3910.24 | -3800.99 | -3543.25 | -3311.77 |
Other Equity, Total | -0.419 | -1.664 | -3.205 | -2.485 | -0.306 |
Total Liabilities & Shareholders’ Equity | 3059.79 | 3128.37 | 3156.15 | 2996.85 | 3056.15 |
Total Common Shares Outstanding | 93.1401 | 87.9501 | 87.7662 | 87.5353 | 87.4956 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Property/Plant/Equipment, Total - Gross | |||||
Accumulated Depreciation, Total |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -703.488 | -418.78 | -554.128 | -715.075 | -361.918 |
Efectivo de actividades de explotación | -325.346 | -443.172 | 107.466 | -456.463 | -388.66 |
Efectivo de actividades de explotación | 41.864 | 38.017 | 26.911 | 30.547 | 12.245 |
Partidas no monetarias | 375.748 | 35.757 | 80.627 | 294.946 | 68.905 |
Intereses pagados en efectivo | 44.418 | 55.949 | 34.418 | 8.55 | 11.308 |
Cambios en el capital circulante | -39.47 | -98.166 | 554.056 | -66.881 | -107.892 |
Efectivo de actividades de inversión | -1046.88 | 495.413 | -121.721 | 286.725 | -370.488 |
Gastos de capital | -30.824 | -38.49 | -82.202 | -62.713 | -64.345 |
Otras partidas de flujo de caja de inversión, total | -1016.06 | 533.903 | -39.519 | 349.438 | -306.143 |
Efectivo procedente de actividades de financiación | 232.507 | 561.569 | 682.323 | 642.554 | 530.15 |
Emisión (retiro) de acciones, neto | -70.945 | 569.334 | 396.01 | 401.955 | 563.631 |
Emisión (amortización) de deuda, neta | 304.168 | 0 | 291.15 | 245.625 | -33.481 |
Variación neta de la tesorería | -1139.72 | 613.81 | 668.068 | 472.816 | -228.998 |
Cash Taxes Paid | 1.695 | 0.583 | 2.51 | 0.933 | 1.548 |
Elementos de flujo de caja de financiación | -0.716 | -7.765 | -4.837 | -5.026 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -516.755 | -703.488 | -594.244 | -336.506 | -105.025 |
Cash From Operating Activities | -209.396 | -325.346 | -232.954 | -167.99 | -101.175 |
Cash From Operating Activities | 11.305 | 41.864 | 31.311 | 20.608 | 10.719 |
Non-Cash Items | 425.11 | 375.748 | 318.056 | 145.971 | 36.648 |
Cash Interest Paid | 7.023 | 44.418 | 41.273 | 27.78 | 11.688 |
Changes in Working Capital | -129.056 | -39.47 | 11.923 | 1.937 | -43.517 |
Cash From Investing Activities | 12.492 | -1046.88 | -1056.68 | -1075.8 | -785.807 |
Capital Expenditures | -9.485 | -30.824 | -22.86 | -14.629 | -5.551 |
Other Investing Cash Flow Items, Total | 21.977 | -1016.06 | -1033.82 | -1061.17 | -780.256 |
Cash From Financing Activities | 101.795 | 232.507 | 221.758 | 5.329 | 4.99 |
Financing Cash Flow Items | -6.887 | -0.716 | -0.162 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 108.682 | -70.945 | -82.248 | 5.329 | 4.99 |
Net Change in Cash | -95.109 | -1139.72 | -1067.88 | -1238.46 | -881.992 |
Issuance (Retirement) of Debt, Net | 304.168 | 304.168 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.693 | 8097450 | 79700 | 2023-03-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 5.2692 | 4908204 | -1119812 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2812 | 3987871 | -30286 | 2023-03-31 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 3.9185 | 3650000 | 475000 | 2023-03-31 | |
Barry (Richard J) | Individual Investor | 3.3584 | 3128319 | 1430 | 2023-04-14 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 3.2201 | 2999453 | 0 | 2023-03-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 3.1494 | 2933612 | 379548 | 2023-03-31 | LOW |
JP Morgan Asset Management | Investment Advisor | 3.1009 | 2888483 | 2405135 | 2023-03-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 2.4401 | 2272877 | 971837 | 2023-03-31 | HIGH |
Fidelity Management & Research Company LLC | Investment Advisor | 2.4199 | 2254083 | 19413 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.9045 | 1773976 | -167768 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3548 | 1261971 | 43239 | 2023-03-31 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.3135 | 1223537 | 25601 | 2023-03-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.3026 | 1213356 | 282713 | 2023-03-31 | LOW |
Casdin Capital, LLC | Hedge Fund | 1.2453 | 1160000 | -155000 | 2023-03-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.2066 | 1123923 | 334496 | 2023-03-31 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.0233 | 953204 | 270542 | 2023-03-31 | LOW |
Farallon Capital Management, L.L.C. | Hedge Fund | 0.9805 | 913300 | -15600 | 2023-03-31 | MED |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.9456 | 880796 | -33023 | 2023-03-31 | LOW |
Sands Capital Management, LLC | Investment Advisor | 0.9391 | 874765 | -1276613 | 2023-03-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group530K+
Traders
87K+
Clientes activos mensualmente
$46M+
Volumen mensual de inversión
$31M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sobre Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. es una empresa biofarmacéutica en fase comercial. La empresa se centra en ayudar a los pacientes mediante el descubrimiento y el desarrollo de terapias dirigidas al ácido ribonucleico (ARN), terapia génica y otras modalidades terapéuticas genéticas para el tratamiento de enfermedades raras. Está desarrollando candidatos terapéuticos para una serie de enfermedades y trastornos, como la distrofia muscular de Duchenne, las distrofias musculares de cinturas y otros trastornos neuromusculares y del sistema nervioso central. Comercializa tres productos, como EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection y AMONDYS 45 (casimersen) Injection. Estos productos comerciales están indicados para el tratamiento de Duchenne en pacientes que tienen una mutación confirmada del gen de la distrofina que es susceptible de omisión del exón 51, exón 53 y exón 45. Su proyecto incluye más de 40 programas en varias etapas de descubrimiento, desarrollo preclínico y clínico.
El precio actual de la acción Sarepta Therapeutics, Inc. en tiempo real es 123.41 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: BRP Group, Inc., Nuvve Holding Corp., Precipio, Inc., MM2 Asia, ThredUp Inc. y Herbalife. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 530.000 traders de todo el mundo que eligen operar con Capital.com